Heron Therapeutics
HRTX
194 hedge funds and large institutions have $2.77B invested in Heron Therapeutics in 2018 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 77 increasing their positions, 61 reducing their positions, and 32 closing their positions.
236% more call options, than puts
Call options by funds: $22.4M | Put options by funds: $6.67M
26% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 61
3% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 32
1% less funds holding
Funds holding: 196 → 194 (-2)
9.42% less ownership
Funds ownership: 122% → 112.57% (-9.4%)
17% less capital invested
Capital invested by funds: $3.33B → $2.77B (-$565M)
27% less funds holding in top 10
Funds holding in top 10: 11 → 8 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Allianz Asset Management
Munich,
Germany
|
+$64.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$61.9M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$30.5M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$23.3M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$15.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$100M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$63.4M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$16.5M |
| 4 |
Renaissance Technologies
New York
|
-$9.62M |
| 5 |
BC
Broadfin Capital
New York
|
-$8.51M |
HRTX Hedge Fund Activity: Q3 2018 in Review
194 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q3 2018, worth a combined $2.77B — down 17% from $3.33B a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of HRTX and 31 opened new positions — a net loss of 1 holder — while 61 trimmed existing stakes and 77 added.
The largest buyer was Allianz Asset Management, adding an estimated $64.1M. The largest seller was Tang Capital Management, cutting an estimated $100M.
- 194 institutional investors held Heron Therapeutics (HRTX) as of Q3 2018, down from 196 in Q2 2018.
- Funds reported $2.77B of Heron Therapeutics stock for Q3 2018, down 17% quarter-over-quarter.
- 31 funds opened new Heron Therapeutics positions in Q3 2018 and 32 closed out, a net change of -1 holder.
- The largest Heron Therapeutics buyer in Q3 2018 was Allianz Asset Management, an estimated $64.1M added.
- The largest Heron Therapeutics seller in Q3 2018 was Tang Capital Management, an estimated $100M sold.
Based on aggregated 13F filings for Q3 2018.